9-16-13 9:24 AM EDT | Email Article
http://media.marketwire.com/attachments/201309/66000_atossa.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1051183&ProfileId=051205&sourceType=1

LOS ANGELES, CA -- (Marketwired) -- 09/16/13 -- Seattle-based Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, today announced its sponsorship of the Los Angeles premiere of Decoding Annie Parker, a new film starring Helen Hunt, tomorrow, September 17, 2013, at the Directors Guild of America, 7920 Sunset Blvd., Los Angeles, CA. Atossa has created the ForeCYTE Breast Health test -- available now -- which non-invasively and painlessly determines the presence of precancerous cells and assesses a women's future risk of breast cancer.

Dr. Steven Quay, Chairman, CEO & President of Atossa Genetics, stated, "Atossa Genetics is singularly focused on assessing breast cancer risk with our ForeCYTE Breast Health Test -- launched in January and available throughout the United States -- and preventing breast cancer by developing and commercializing an investigative intraductal therapy approach to treat pre-cancerous abnormalities, including ductal carcinoma in situ.

"Recent news stories about the increasing number of women with BRCA1 gene mutations having prophylactic bilateral mastectomy to reduce the risk of breast cancer have thrust the entire area of breast cancer risk assessment and prevention to the fore. We believe that our ForeCYTE Breast Health Test, which analyzes cells from the linings of the milk ducts where approximately 95 percent of breast cancers arise, provides women and their doctors with crucial information upon which to make more informed treatment decisions. For all those women who are concerned about their risk of breast cancer or who may be considering preventive bilateral mastectomy, we believe our test provides crucial information that will have a direct bearing on the decision making process," Dr. Quay added.

Decoding Annie Parker, directed by Steven Bernstein, honors the lives of two inspirational women impacted by breast cancer: Dr. Marie-Claire King, a geneticist at the University of Washington, who defied medical convention by looking for and finding the BRCA1 gene, now known to cause breast cancer, and Ann Parker, who struggles with breast cancer on more intimate terms after being diagnosed with breast cancer herself and having had to watch both her mother and sister succumb to the disease. The film stars Helen Hunt, who gives yet another inspiring performance in the role of Dr. King in her singular quest for the breast cancer gene.

"I am very excited about the potential of Atossa's ForeCYTE Breast Health Test to help prevent breast cancer so that fewer women will receive a devastating diagnosis or have to endure months or years of treatment," stated Steven Bernstein, Director of Decoding Annie Parker. "I am pleased to support Atossa Genetics in its quest to prevent breast cancer by producing a 90-second commercial on the ForeCYTE test, which will be shown tomorrow for the first time at the Los Angeles premier of Decoding Annie Parker."

Additional information about Decoding Annie Parker is available at http://www.decodingannieparkerfilm.com/.

Atossa Genetics is proud to co-sponsor Decoding Annie Parker and to support the efforts of Dr. King's lab at the University of Washington and its mission to further understand the role of genetics of breast cancer.

About the ForeCYTE Breast Health Test

The ForeCYTE Breast Health Test, intended for the 110 million women in the U.S. ages 18 to 73, is a painless, quick and non-invasive procedure that can be done in a physician's office. The test specimens are then analyzed at Atossa's laboratory, The National Reference Laboratory for Breast Health, Inc. (NRLBH), which can provide vital early detection of cancer or pre-cancerous conditions that may progress to cancer over an approximately eight year period and before cancer can be detected by mammography or other means and without the risks of radiation, especially in women younger than age 50. No invasive biopsy needles or open surgical incisions are used in the Atossa test.

Just as the Pap smear has reduced cervical cancer rates by over 70 percent, becoming the most successful screening test in medicine, the goal of Atossa Genetics is to reduce the stubbornly high rate of breast cancer through the early detection of the precursor changes that can lead to breast cancer and the treatment of those early changes. For more information, please visit getforecyte.com.

About Atossa Genetics, Inc.

Atossa Genetics, Inc. is focused on preventing breast cancer through the commercialization of patented, FDA-designated Class II diagnostic medical devices and, through its wholly-owned subsidiary, The NRLBH, patented, laboratory developed tests that can detect precursors to breast cancer up to eight years before mammography.

The NRLBH is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, Washington.

For additional information, on Atossa and the NRLBH, please visit www.atossagenetics.com and www.nrlbh.com. For further information on the ForeCYTE Breast Health Test, please visit www.getforecyte.com.

Forward-Looking Statements

Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, regulatory clearances, responses to regulatory matters, Atossa's ability to continue to manufacture and sell its products, the efficacy of Atossa's products and services, the market demand for and acceptance of Atossa's products and services, performance of distributors and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

Add to Digg Bookmark with del.icio.us Add to Newsvine


Atossa Genetics, Inc.
Chris Destro
Vice President, Sales & Marketing
(O) 800-351-3902
(M) 206-310-2335
Email Contact

MBS Value Partners, LLC (Investors)
Matthew D. Haines
Managing Director
(O) 212-710-9686
Email Contact

JQA Partners, LLC (media)
Jules Abraham
(O) 917-885-7378
Email Contact

Add a Comment

News   More...

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar

Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Content Partners
Morningstar - - Atossa Genetics Co-Sponsors Los Angeles Premiere of Decoding Annie Parker, Starring Helen Hunt
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Author |  Collection |  Interest |  Popularity

Previous: Atossa Genetics Announces Two Scientific Presentations at the 2013 San Antonio Breast Cancer Symposium  |  Next: Atossa Genetics Conference Call and Webcast Notice